<DOC>
	<DOCNO>NCT00498914</DOCNO>
	<brief_summary>A study subject type B cell lymphoma ( DLBCL ) evaluate response rate , efficacy , safety tolerability YM155</brief_summary>
	<brief_title>Study YM155 Refractory Diffuse Large B-cell Lymphoma ( DLBCL ) Subjects</brief_title>
	<detailed_description>1 arm ( Active ) , Phase 2 Study evaluate response rate , efficacy , safety tolerability YM155</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Male female subject age 18 year old Histologically confirm primary DLBCL stage Refractory last treatment regimen Previously treat follow treatment regimen : Anthracyclinebased combination chemotherapy rituximab Secondline combination chemotherapy Autologous BMT subject eligible refuse procedure At least one measurable lesion define &gt; 1.5 cm long diameter No known central nervous system involvement ECOG performance status &lt; 2 Life expectancy &gt; 12 week If female , nonpregnant nonlactating IRBapproved consent HIPAA Authorization Transformed , composite discordant lymphoma Therapy lymphoma within 21 day prior first dose YM155 Within 4 week screen FDGPET scan , receipt following : Radiation therapy Surgical procedure ( except biopsy central catheter / port placement ) Active infection ( bloodstream deep tissue ) Inadequate marrow , hepatic and/or renal function Serum creatinine &gt; 1.5 x ULN calculate serum creatinine clearance &lt; 60 mL/min Absolute Neutrophil Count ( ANC ) &lt; 750/mm3 Platelet &lt; 50,000/mm3 Alanine Transaminase ( ALT ) Aspartate Transaminase ( AST ) &gt; 2.5 x ULN ; &gt; 5 x ULN secondary liver metastasis Treated &gt; 3 prior treatment regimen . The following consider : Planned maintenance therapy consider part previous treatment regimen Any preparative treatment ( salvage chemotherapy , highdose chemotherapy , radiation therapy , etc . ) include autologous BMT PBSCT one treatment Prior allogeneic BMT PBSCT Previously treat YM155 Other investigational therapy procedure within 28 day Known HIV , hepatitis B surface antigen , hepatitis C antibody Other malignancy require treatment within 2 year Significant and/or uncontrolled cardiac , renal , hepatic , systemic disorder significant psychological condition Investigator 's judgment would jeopardize subject enrollment compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Lymphoma , Large-Cell , Diffuse</keyword>
	<keyword>Lymphoma , B-Cell</keyword>
	<keyword>YM155</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Refractory</keyword>
</DOC>